Correction to: Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells

Yahui Ding,Huier Gao,Yu Zhang,Ye Li,Neil Vasdev,Yingdai Gao,Yue Chen,Quan Zhang

DOI: https://doi.org/10.1186/s13045-021-01069-3

2021-04-15

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology,hematology

What problem does this paper attempt to address?

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Xi Jiang,Chao Hu,Kyle Ferchen,Ji Nie,Xiaolong Cui,Chih-Hong Chen,Liting Cheng,Zhixiang Zuo,William Seibel,Chunjiang He,Yixuan Tang,Jennifer R. Skibbe,Mark Wunderlich,William C. Reinhold,Lei Dong,Chao Shen,Stephen Arnovitz,Bryan Ulrich,Jiuwei Lu,Hengyou Weng,Rui Su,Huilin Huang,Yungui Wang,Chenying Li,Xi Qin,James C. Mulloy,Yi Zheng,Jiajie Diao,Jie Jin,Chong Li,Paul P. Liu,Chuan He,Yuan Chen,Jianjun Chen

DOI: https://doi.org/10.1038/s41467-018-02947-0

IF: 16.6

2018-01-01

Nature Communications

Abstract:The original version of this Article contained an error in the spelling of the author James C. Mulloy, which was incorrectly given as James Mulloy. This has now been corrected in both the PDF and HTML versions of the Article.
Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Chao Hu,Mengxia Yu,Yanling Ren,Kongfei Li,Dominic M. Maggio,Chen Mei,Li Ye,Juying Wei,Jie Jin,Zhengping Zhuang,Hongyan Tong

DOI: https://doi.org/10.1038/s41598-017-14858-z

IF: 4.6

2017-01-01

Scientific Reports

Abstract:correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.
Targeted Inhibition Of Stat/Tet1 Axis As A Therapeutic Strategy For Acute Myeloid Leukemia (Vol 8, 2017)

Xi Jiang,Chao Hu,Kyle Ferchen,Ji Nie,Xiaolong Cui,Chih-Hong Chen,Liting Cheng,Zhixiang Zuo,William Seibel,Chunjiang He,Yixuan Tang,Jennifer R. Skibbe,Mark Wunderlich,William C. Reinhold,Lei Dong,Chao Shen,Stephen Arnovitz,Bryan Ulrich,Jiuwei Lu,Hengyou Weng,Rui Su,Huilin Huang,Yungui Wang,Chenying Li,Xi Qin,James C. Mulloy,Yi Zheng,Jiajie Diao,Jie Jin,Chong Li,Paul Liu,Chuan He,Yuan Chen,Jianjun Chen

DOI: https://doi.org/10.1038/s41467-018-02947-0

IF: 16.6

2018-01-01

Nature Communications

Abstract:The original version of this Article contained an error in the spelling of the author James C. Mulloy, which was incorrectly given as James Mulloy. This has now been corrected in both the PDF and HTML versions of the Article.
Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Xia Li,Xiufeng Yin,Huafeng Wang,Jiansong Huang,Mengxia Yu,Zhixin Ma,Chenying Li,Yile Zhou,Xiao Yan,ShuJuan Huang,Jie Jin

DOI: https://doi.org/10.18632/oncotarget.27310

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.14463.].
Correction: Allogeneic Hematopoietic Stem Cell Transplantation Should Be in Preference to Conventional Chemotherapy As Post-Remission Treatment for Adults with Lymphoblastic Lymphoma

Luxin Yang,Yamin Tan,Jimin Shi,Yanmin Zhao,Yuanyuan Zhu,Yongxian Hu,Wenjue Pan,Yishan Ye,Jingsong He,Weiyan Zheng,Jie Sun,Zhen Cai,He Huang,Yi Luo

DOI: https://doi.org/10.1038/s41409-020-0962-x

2020-01-01

Bone Marrow Transplantation

Abstract:An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Pp2a Inhibition From Lb100 Therapy Enhances Daunorubicin Cytotoxicity In Secondary Acute Myeloid Leukemia Via Mir-181b-1 Upregulation (Vol 7, 2894, 2017)

Chao Hu,Mengxia Yu,Yanling Ren,Kongfei Li,Dominic Maggio,Chen Mei,Li Ye,Juying Wei,Jie Jin,Zhengping Zhuang,Hongyan Tong

DOI: https://doi.org/10.1038/s41598-017-14858-z

IF: 4.6

2017-01-01

Scientific Reports

Abstract:A correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.
Correction to: Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβkinase activity and interrupting NF-κB/COX-2-mediated signaling cascades

Xun Wang,Zhenlong Yu,Chao Wang,Wei Cheng,Xiangge Tian,Xiaokui Huo,Yan Wang,Chengpeng Sun,Lei Feng,Jinshan Xing,Yulong Lan,Dongdong Sun,Qingjuan Hou,Baojing Zhang,Xiaochi Ma,Bo Zhang

DOI: https://doi.org/10.1186/s13046-020-01699-4

2020-09-23

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology
Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl

Zhongzheng Lu,Yanli Jin,Chun Chen,Juan Li,Qi Cao,Jingxuan Pan

DOI: https://doi.org/10.1186/s12943-021-01414-7

IF: 37.3

2021-12-01

Molecular Cancer

Abstract:An amendment to this paper has been published and can be accessed via the original article.

oncology,biochemistry & molecular biology
Author Correction: CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia

Guozhu Xie,Nikola A. Ivica,Bin Jia,Yingzhong Li,Han Dong,Yong Liang,Douglas Brown,Rizwan Romee,Jianzhu Chen

DOI: https://doi.org/10.1038/s41551-020-00677-7

IF: 28.1

2020-12-16

Nature Biomedical Engineering

Abstract:A Correction to this paper has been published: https://doi.org/10.1038/s41551-020-00677-7

engineering, biomedical
Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia

Shi Hao Tan,Tze King Tan,Rui Yokomori,Minghui Liao,Xiao Zi Huang,Allen Eng Juh Yeoh,Takaomi Sanda

DOI: https://doi.org/10.1038/s41375-023-02125-2

2024-01-26

Leukemia

Abstract:Leukemia, Published online: 25 January 2024; doi:10.1038/s41375-023-02125-2 Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia

oncology,hematology
Correction: Corrigendum: Inhibitory Receptors Bind ANGPTLs and Support Blood Stem Cells and Leukaemia Development

Junke Zheng,Masato Umikawa,Changhao Cui,Jiyuan Li,Xiaoli Chen,Chaozheng Zhang,HoangDinh Huynh,Xunlei Kang,Robert Silvany,Xuan Wan,Jingxiao Ye,Alberto Puig Cantó,Shu-Hsia Chen,Huan-You Wang,E. Sally Ward,Cheng

DOI: https://doi.org/10.1038/nature11268

IF: 64.8

2012-01-01

Nature

Abstract:Nature 485, 656–660 (2012); doi:10.1038/nature11095 The surname of author HoangDinh Huynh was inadvertently misspelled as Hyunh. This has been corrected online in the PDF and HTML of the original paper.
[Corrigendum] Role of 4‑aminobutyrate Aminotransferase (ABAT) and the Lncrna Co‑expression Network in the Development of Myelodysplastic Syndrome

Yanzhen Chen,Guangjie Zhao,Nianyi Li,Hongguang Luo,Xiaoqin Wang,Jingwen Gu

DOI: https://doi.org/10.3892/or.2022.8447

2022-01-01

Oncology Reports

Abstract:Subsequently to the publication of the above article, and a Corrigendum that has already been published with the intention of showing corrected versions of Figs. 1 and 8 (DOI: 10.3892/or.2022.8348; published online on June 14, 2022), the authors have belatedly realized that the revisions made to Fig. 8 necessitated changes that should have been introduced into Fig. 9, although these were not attended to in the first corrigendum. Essentially, Fig. 8 was revised as the cell apoptosis and cell proliferation assays therein were poorly presented, which made the interpretation of the data difficult; Fig. 9 showed the fractions of apoptotic cells in the SKM‑1 and THP‑1 cell lines with lncENST00000444102 overexpression as this pertained to Fig. 8. A revised version of Fig. 9, presenting the analysis of the data shown in the revised version of Fig. 8, is shown opposite. In addition to the revision of Fig. 9, the sentence starting on p. 517, left‑hand column, line 12 [“The flow cytometric apoptosis assay revealed that lncENST00000444102 overexpression promoted tumor cells to undergo apoptosis compared to control cells (P<0.001, Fig. 9)”] should be replaced with the following text, to reflect the change in the level of statistical significance: ‘The flow cytometric apoptosis assay revealed that lncENST00000444102 overexpression promoted tumor cells to undergo apoptosis compared to control cells (P<0.01, Fig. 9)”. Note that the revisions made to Figs. 8 and 9 in this paper have not had a major impact on the reported results, and do not affect the overall conclusions reported in the study. All the authors agree to the publication of this corrigendum. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this additional Corrigendum; furthermore, they apologize for any inconvenience caused to the readership of the Journal. [Oncology Reports 42: 509‑520, 2019; DOI: 10.3892/or.2019.7175]
Correction: Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer

Song, Xuejiao,Gao, Tiantao,Wang, Ningyu,Feng, Qiang,You, Xinyu,Ye, Tinghong,Lei, Qian,Zhu, Yongxia,Xiong, Menghua,Xia, Yong,Yang, Fangfang,Shi, Yaojie,Wei, Yuquan,Zhang, Lidan,Yu, Luoting

DOI: https://doi.org/10.1038/srep20864

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Scientific Reports 6: Article number: 20864; Published online: 12 February 2016; Updated: 29 April 2016 This Article contains typographical errors. In the Results section under subheading ‘Impact of ZLD1039 on breast cancer cell growth’, “Among the cell lines, MCF-7 and ZR-75-1 were the most sensitive to ZLD1039 with IC50 values of 0.
Correction To: Salinomycin Effectively Eliminates Cancer Stem-Like Cells and Obviates Hepatic Metastasis in Uveal Melanoma

Zhou Jingfeng,Liu Shenglan,Wang Yun,Dai Wei,Zou Hailin,Wang Shubo,Zhang Jing,Pan Jingxuan

DOI: https://doi.org/10.1186/s12943-021-01334-6

IF: 37.3

2021-01-01

Molecular Cancer

Abstract:An amendment to this paper has been published and can be accessed via the original article.
Correction: Alpl prevents bone ageing sensitivity by specifically regulating senescence and differentiation in mesenchymal stem cells

Wenjia Liu,Liqiang Zhang,Kun Xuan,Chenghu Hu,Shiyu Liu,Li Liao,Bei Li,Fang Jin,Songtao Shi,Yan Jin

DOI: https://doi.org/10.1038/s41413-020-00107-z

IF: 12.7

2020-07-28

Bone Research

Abstract:An amendment to this paper has been published and can be accessed via a link at the top of the paper.

cell & tissue engineering
Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Yifeng Xia,Jingnan An,Jiaying Li,Wenxing Gu,Yifan Zhang,Songsong Zhao,Cenzhu Zhao,Yang Xu,Bin Li,Zhiyuan Zhong,Fenghua Meng

DOI: https://doi.org/10.1016/j.bioactmat.2023.08.011

IF: 18.9

2024-01-01

Bioactive Materials

Abstract:[This corrects the article DOI: 10.1016/j.bioactmat.2022.08.032.].
Corrigendum: High expression level of the FTH1 gene is associated with poor prognosis in children with non-M3 acute myeloid leukemia

Junlin Zhang,Liying Liu,Jinshuang Wei,Xiaojing Wu,Jianming Luo,Hongying Wei,Liao Ning,Yunyan He

DOI: https://doi.org/10.3389/fonc.2023.1212991

2023-08-21

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.1068094.].
Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Xiaowen Tang,Lin Yang,Zheng Li,Ansel P Nalin,Haiping Dai,Ting Xu,Jia Yin,Fengtao You,Mingqing Zhu,Wenhong Shen,Guanghua Chen,Xiaming Zhu,Depei Wu,Jianhua Yu

2018-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 1083 in vol. 8, PMID: 30034945.].
Correction to: Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

Ju Bai,Aili He,Chen Huang,Juan Yang,Wanggang Zhang,Jianli Wang,Yun Yang,Pengyu Zhang,Yang Zhang,Fuling Zhou

DOI: https://doi.org/10.1186/s12953-020-00166-4

2020-01-01

Proteome Science

Abstract:An amendment to this paper has been published and can be accessed via the original article.
Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Leukemia' [Biology of Blood and Marrow Transplantation 23/8 (2017) 1311-1319].

Chen-Hua Yan,Qi-Fa Liu,De-Pei Wu,Xi Zhang,Lan-Ping Xu,Xiao-Hui Zhang,Yu Wang,He Huang,Hai Bai,Fen Huang,Xiao Ma,Xiao-Jun Huang

DOI: https://doi.org/10.1016/j.bbmt.2019.03.006

2019-01-01

Abstract:The authors regret that in the above-mentioned article, the description “…4-color flow cytometry (FCM)” (Lines 30-31, right column, Page 1312) was incorrectly. The correct description should be “….8-color flow cytometry (FCM)”. The authors would like to apologise for any inconvenience caused. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute LeukemiaBiology of Blood and Marrow TransplantationVol. 23Issue 8PreviewPatients with refractory/relapsed acute leukemia who have received allogeneic hematopoietic stem cell transplantation (allo-HSCT) are still at a high risk for relapse post-transplant. To investigate the impact of prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease (MRD) test and graft-versus-host disease (GVHD)–guided multiple DLIs to prevent relapse and improve survival in patients with refractory/relapsed acute leukemia who received allo-HSCT. A multicenter prospective study was designed. Full-Text PDF Open Archive

Correction to: Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Targeted Inhibition Of Stat/Tet1 Axis As A Therapeutic Strategy For Acute Myeloid Leukemia (Vol 8, 2017)

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Correction: Allogeneic Hematopoietic Stem Cell Transplantation Should Be in Preference to Conventional Chemotherapy As Post-Remission Treatment for Adults with Lymphoblastic Lymphoma

Pp2a Inhibition From Lb100 Therapy Enhances Daunorubicin Cytotoxicity In Secondary Acute Myeloid Leukemia Via Mir-181b-1 Upregulation (Vol 7, 2894, 2017)

Correction to: Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβkinase activity and interrupting NF-κB/COX-2-mediated signaling cascades

Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl

Author Correction: CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia

Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia

Correction: Corrigendum: Inhibitory Receptors Bind ANGPTLs and Support Blood Stem Cells and Leukaemia Development

[Corrigendum] Role of 4‑aminobutyrate Aminotransferase (ABAT) and the Lncrna Co‑expression Network in the Development of Myelodysplastic Syndrome

Correction: Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer

Correction To: Salinomycin Effectively Eliminates Cancer Stem-Like Cells and Obviates Hepatic Metastasis in Uveal Melanoma

Correction: Alpl prevents bone ageing sensitivity by specifically regulating senescence and differentiation in mesenchymal stem cells

Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]

Corrigendum: High expression level of the FTH1 gene is associated with poor prognosis in children with non-M3 acute myeloid leukemia

Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Correction to: Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia